Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

French cities launch community push to wipe out hepatitis c in drug users

NCT ID NCT05794646

Disease control Sponsor: ANRS, Emerging Infectious Diseases Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study aims to eliminate hepatitis C among people who use drugs in Paris, Marseille, Lyon, and Fort-de-France. Researchers will screen participants, provide immediate treatment, and use a peer-referral system to reach more people. The goal is to see if this community-based approach can effectively cure hepatitis C and reduce its spread.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hepatitis C antiviral treatment
What this could lead to
If successful, this could show a practical way to eliminate hepatitis C in high-risk communities, reducing transmission and liver disease.
What could go wrong
This is an implementation study, not a drug trial, so it tests feasibility rather than a new cure. Success depends on community participation and follow-up, which may be challenging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 3,400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Sep 2025

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * Age \> 18 years; * Person who uses drugs, defined as: * Reported psychoactive substance use and * Positive urine test for at least one of the following: heroin, amphetamines, cocaine, MDMA (methylenedioxymethamphetamine), ecstasy, or misused opioid medications (methadone, buprenorphine or opiates used for a reason other than its original prescription (effects seeking) or used in a way that does not comply with its marketing authorisation (injected, snorted, taken multiple times beyond the prescribed dosage)) ; * Informed and signed consent Exclusion criteria: * Inability to understand the study; * Being under guardianship, curatorship or mandate of future protection; * Person participating in another research study with an exclusion period still in progress at the time of pre-inclusion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection Psychological Well-Being substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCV Substance use disorders

Contacts and locations

Locations

  • Lyon

    Lyon, Auvergne-Rhône-Alpes, 69000, France

  • Marseille

    Marseille, PACA, 13000, France

  • Martinique

    Fort-de-France, Martinique, 97200, Martinique

  • Paris

    Paris, Île-de-France Region, 75000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.